<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118789</url>
  </required_header>
  <id_info>
    <org_study_id>NVL-520-01</org_study_id>
    <nct_id>NCT05118789</nct_id>
  </id_info>
  <brief_title>A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)</brief_title>
  <official_title>A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuvalent Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuvalent Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1/2, dose escalation and expansion study designed to evaluate the safety and&#xD;
      tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the&#xD;
      antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced&#xD;
      ROS1-positive solid tumors.&#xD;
&#xD;
      Phase 1 will determine the RP2D and/or maximum tolerated dose (MTD) of NVL-520 in patients&#xD;
      with advanced ROS1-positive solid tumors.&#xD;
&#xD;
      Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent&#xD;
      Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration&#xD;
      of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival&#xD;
      (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive&#xD;
      NSCLC and other solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase 2, study patients will be enrolled into 5 distinct expansion cohorts:&#xD;
&#xD;
        -  Cohort 2a: ROS1-positive NSCLC naïve to Tyrosine Kinase Inhibitor (TKI) therapy.&#xD;
&#xD;
        -  Cohort 2b: ROS1-positive NSCLC treated with 1 prior ROS1 TKI and no prior platinum-based&#xD;
           chemotherapy with or without immunotherapy.&#xD;
&#xD;
        -  Cohort 2c: ROS1-positive NSCLC treated with 1 prior ROS1 TKI and 1 prior platinum-based&#xD;
           chemotherapy with or without immunotherapy.&#xD;
&#xD;
        -  Cohort 2d: ROS1-positive NSCLC treated with ≥2 prior ROS1 TKIs and up to 1 prior&#xD;
           platinum-based chemotherapy with or without immunotherapy.&#xD;
&#xD;
        -  Cohort 2e: ROS1-positive solid tumor and progressed on any prior therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) (Phase 1)</measure>
    <time_frame>Within the first 28 days of the first NVL-520 dose</time_frame>
    <description>Define the dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Within 28 days of last patient dosed during dose escalation.</time_frame>
    <description>To determine the RP2D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (Phase 2)</measure>
    <time_frame>2-3 years after first patient dosed.</time_frame>
    <description>To determine ORR as assessed by BICR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events, as assessed by CTCAE, v5.0</measure>
    <time_frame>Approximately 3 years.</time_frame>
    <description>Incidence and severity of treatment-emergent adverse events (TEAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the maximum plasma concentration (Cmax) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at the end of the dosing interval (Ctau) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the plasma concentration at the end of the dosing interval (Ctau) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average plasma concentration (Cavg) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the average plasma concentration (Cavg) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the time of maximum concentration (Tmax) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve at the end of the dosing interval (AUCtau) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the area under the curve at the end of the dosing interval (AUCtau) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to 24 (AUC0-24) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the area under the curve from time 0 to 24 (AUC0-24) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time 0 to infinity (AUCinf) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the area under the curve from time 0 to infinity (AUCinf) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the oral clearance (CL/F) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/F) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the volume of distribution (Vz/F) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of NVL-520</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
    <description>To determine the half-life (t1/2) of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2-3 years after first patient dosed</time_frame>
    <description>Determine ORR as assessed by BICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2-3 years after first patient dosed</time_frame>
    <description>Determine DOR of NVL-520 until radiographic disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>2-3 years after first patient dosed</time_frame>
    <description>Determine CBR of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Determine time to response of NVL-520</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2-3 years after first patient dosed</time_frame>
    <description>Determine PFS of NVL-520 until radiographic disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Determine OS</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>Locally Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVL-520 oral daily dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ROS1+ NSCLC naïve to TKI therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ROS1+ NSCLC treated with 1 prior ROS1 TKI and no prior platinum-based chemotherapy or immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ROS1+ NSCLC treated with 1 prior ROS1 TKI and 1 prior platinum-based chemotherapy with or without immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ROS1+ NSCLC treated with ≥2 prior ROS1 TKIs and up to 1 prior platinum-based chemotherapy with or without immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2e</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ROS1+ solid tumor and progressed on any prior therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVL-520</intervention_name>
    <description>Oral tablet of NVL-520</description>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_label>Cohort 2c</arm_group_label>
    <arm_group_label>Cohort 2d</arm_group_label>
    <arm_group_label>Cohort 2e</arm_group_label>
    <arm_group_label>Phase 1 dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years (Cohort 2e only: Age ≥12 years and weighing&gt;40 kg).&#xD;
&#xD;
          2. Phase 1:&#xD;
&#xD;
               1. Histologically or cytologically confirmed metastatic solid tumor with documented&#xD;
                  ROS1 rearrangement.&#xD;
&#xD;
               2. Cohorts 2a, 2b, 2c and 2d: Histologically or cytologically confirmed metastatic&#xD;
                  NSCLC with ROS1 rearrangement.&#xD;
&#xD;
               3. Cohort 2e: Histologically or cytologically confirmed metastatic solid tumor&#xD;
                  (other than NSCLC) with ROS1 rearrangement.&#xD;
&#xD;
          3. Prior anticancer treatment (except cohort 2a).&#xD;
&#xD;
          4. Phase 1: Must have evaluable disease (target or nontarget) according to RECIST 1.1.&#xD;
             Phase 2: Must have measurable disease according to RECIST 1.1.&#xD;
&#xD;
          5. Adequate baseline organ function and bone marrow reserve.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient's cancer has a known primary driver alteration other than ROS1.&#xD;
&#xD;
          2. Known allergy/hypersensitivity to excipients of NVL-520.&#xD;
&#xD;
          3. Major surgery within 4 weeks of study entry.&#xD;
&#xD;
          4. Ongoing or recent anticancer therapy.&#xD;
&#xD;
          5. Actively receiving systemic treatment or direct medical intervention on another&#xD;
             therapeutic clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viola Zhu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nuvalent Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gosia Riley</last_name>
    <phone>857-357-7000</phone>
    <email>griley@nuvalent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

